CD19 and lymphoma: The lymphoma-free survival of the control mice without Mcl-1 deletion (Eμ-Myc and Eμ-Myc;CD19-Cre) was similar: median survivals of 91 days and 117 days, respectively (Mantle–Cox Log-rank test P=0.069, Figure 1a).